Literature DB >> 12218188

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Yoshiko Iwai1, Masayoshi Ishida, Yoshimasa Tanaka, Taku Okazaki, Tasuku Honjo, Nagahiro Minato.   

Abstract

PD-1 is a receptor of the Ig superfamily that negatively regulates T cell antigen receptor signaling by interacting with the specific ligands (PD-L) and is suggested to play a role in the maintenance of self-tolerance. In the present study, we examined possible roles of the PD-1/PD-L system in tumor immunity. Transgenic expression of PD-L1, one of the PD-L, in P815 tumor cells rendered them less susceptible to the specific T cell antigen receptor-mediated lysis by cytotoxic T cells in vitro, and markedly enhanced their tumorigenesis and invasiveness in vivo in the syngeneic hosts as compared with the parental tumor cells that lacked endogenous PD-L. Both effects could be reversed by anti-PD-L1 Ab. Survey of murine tumor lines revealed that all of the myeloma cell lines examined naturally expressed PD-L1. Growth of the myeloma cells in normal syngeneic mice was inhibited significantly albeit transiently by the administration of anti-PD-L1 Ab in vivo and was suppressed completely in the syngeneic PD-1-deficient mice. These results suggest that the expression of PD-L1 can serve as a potent mechanism for potentially immunogenic tumors to escape from host immune responses and that blockade of interaction between PD-1 and PD-L may provide a promising strategy for specific tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218188      PMCID: PMC129438          DOI: 10.1073/pnas.192461099

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  ICOS is essential for effective T-helper-cell responses.

Authors:  A Tafuri; A Shahinian; F Bladt; S K Yoshinaga; M Jordana; A Wakeham; L M Boucher; D Bouchard; V S Chan; G Duncan; B Odermatt; A Ho; A Itie; T Horan; J S Whoriskey; T Pawson; J M Penninger; P S Ohashi; T W Mak
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

2.  Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

Authors:  Masayoshi Ishida; Yoshiko Iwai; Yoshimasa Tanaka; Taku Okazaki; Gordon J Freeman; Nagahiro Minato; Tasuku Honjo
Journal:  Immunol Lett       Date:  2002-10-21       Impact factor: 3.685

3.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

4.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

5.  Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens.

Authors:  Y Kato; Y Tanaka; F Miyagawa; S Yamashita; N Minato
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

6.  Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected.

Authors:  L Ramarathinam; S Sarma; M Maric; M Zhao; G Yang; L Chen; Y Liu
Journal:  J Immunol       Date:  1995-12-01       Impact factor: 5.422

Review 7.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

8.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

Authors:  A Y Huang; P Golumbek; M Ahmadzadeh; E Jaffee; D Pardoll; H Levitsky
Journal:  Science       Date:  1994-05-13       Impact factor: 47.728

9.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

10.  The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.

Authors:  B Van den Eynde; B Lethé; A Van Pel; E De Plaen; T Boon
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

View more
  1040 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 2.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

3.  Lenalidomide enhances anti-myeloma cellular immunity.

Authors:  Katarina Luptakova; Jacalyn Rosenblatt; Brett Glotzbecker; Heidi Mills; Dina Stroopinsky; Turner Kufe; Baldev Vasir; Jon Arnason; Dimitri Tzachanis; Jeffrey I Zwicker; Robin M Joyce; James D Levine; Kenneth C Anderson; Donald Kufe; David Avigan
Journal:  Cancer Immunol Immunother       Date:  2012-06-24       Impact factor: 6.968

4.  Naive CD4+ T Cells Carrying a TLR2 Agonist Overcome TGF-β-Mediated Tumor Immune Evasion.

Authors:  Mohsen Ibrahim; Davide Scozzi; Kelsey A Toth; Donatella Ponti; Daniel Kreisel; Cecilia Menna; Elena De Falco; Antonio D'Andrilli; Erino A Rendina; Antonella Calogero; Alexander S Krupnick; Andrew E Gelman
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

Review 5.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

Review 6.  Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.

Authors:  M Segovia; S Russo; M R Girotti; G A Rabinovich; M Hill
Journal:  Clin Exp Immunol       Date:  2020-05       Impact factor: 4.330

7.  In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression.

Authors:  Akio Ohta; J Kjaergaard; S Sharma; M Mohsin; N Goel; M Madasu; E Fradkov; Akiko Ohta; M Sitkovsky
Journal:  Br J Pharmacol       Date:  2008-12-09       Impact factor: 8.739

8.  Detection of binding of a synthetic granzyme B-like peptide fluorescent conjugate within platelet-like structures in cancer-related peripheral blood specimens and tissue sections.

Authors:  Wai Chun Jennifer Lo; Donald Gene Luther
Journal:  J Fluoresc       Date:  2014-08-07       Impact factor: 2.217

Review 9.  Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Authors:  Christophoros Astaras; Rita de Micheli; Bianca Moura; Thomas Hundsberger; Andreas F Hottinger
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-01       Impact factor: 5.081

Review 10.  Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Nat Rev Clin Oncol       Date:  2013-11-12       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.